B. Riley raised the firm’s price target on Radiopharm (RADX) to $16 from $13 and keeps a Buy rating on the shares. Radiopharm reported positive interim Phase 2b imaging data for RAD101 in brain metastases, with 92% MRI concordance and clear, selective tumor uptake consistent with prior Phase 2a results, the analyst tells investors in a research note. Enrollment is over 50% in the 30-patient study, with final data expected in the first half of 2026 to inform Phase 3 design ahead of a planned FDA meeting in mid-2026, B. Riley adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Why Is Radiopharm Theranostics Stock (RADX) Up Today?
- Radiopharm achieves primary endpoint in 92% of patients in RAD 101 trial
- Radiopharm Theranostics Announces Successful General Meeting Resolutions
- Radiopharm price target lowered to $13 from $15 at B. Riley